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ABSTRACT: Polymer masked−unmasked protein therapy (PUMPT) uses conjugation of a biodegradable polymer, such as
dextrin, hyaluronic acid, or poly(L-glutamic acid), to mask a protein or peptide’s activity; subsequent locally triggered
degradation of the polymer at the target site regenerates bioactivity in a controllable fashion. Although the concept of PUMPT
is well established, the relationship between protein unmasking and reinstatement of bioactivity is unclear. Here, we used
dextrin−colistin conjugates to study the relationship between the molecular structure (degree of unmasking) and biological
activity. Size exclusion chromatography was employed to collect fractions of diﬀerentially degraded conjugates and
ultraperformance liquid chromatography−mass spectrometry (UPLC−MS) employed to characterize the corresponding
structures. Antimicrobial activity was studied using a minimum inhibitory concentration (MIC) assay and confocal laser
scanning microscopy of LIVE/DEAD-stained bioﬁlms with COMSTAT analysis. In vitro toxicity of the degraded conjugate was
assessed using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. UPLC−MS revealed that the fully
“unmasked” dextrin−colistin conjugate composed of colistin bound to at least one linker, whereas larger species were composed
of colistin with varying lengths of glucose units attached. Increasing the degree of dextrin modiﬁcation by succinoylation
typically led to a greater number of linkers bound to colistin. Greater antimicrobial and antibioﬁlm activity were observed for
the fully “unmasked” conjugate compared to the partially degraded species (MIC = 0.25 and 2−8 μg/mL, respectively), whereas
dextrin conjugation reduced colistin’s in vitro toxicity toward kidney cells, even after complete unmasking. This study highlights
the importance of deﬁning the structure−antimicrobial activity relationship for novel antibiotic derivatives and demonstrates the
suitability of LC−MS to aid the design of biodegradable polymer−antibiotic conjugates.
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1. INTRODUCTION
The emergence of antibiotic-resistant bacteria represents a
major global health threat and a signiﬁcant clinical and societal
challenge. Of particular concern is the rapidly increasing
resistance rate of many Gram-negative bacterial pathogens,
which has been mirrored by a decrease in research and
development of new antibiotic compounds.1 In 2018, the
World Health Organization (WHO) published a list of
pathogens posing the greatest threat to human health.2 The
most critical pathogen group includes Pseudomonas aeruginosa,
Acinetobacter baumannii, and Enterobacteriaceae (which
includes Klebsiella pneumoniae and Escherichia coli) because
of high levels of drug resistance and severity of infection in
hospitals, nursing homes, and among critically ill and elderly
patients.
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Although progress remains to be made in the development
of new classes of antibiotics, older “drugs of last resort” such as
colistin are increasingly being employed3,4 as, despite higher
incidences of toxicity and signiﬁcant long-term complications,
they have retained antimicrobial eﬃcacy. Colistin (also known
as polymyxin E) is a cationic peptide from the polymyxin
family of antibiotics. It was isolated from Bacillus colistinus in
1947 and has been on the market as a treatment for Gram-
negative bacterial infections since 1950.5 Several years later,
however, reports of dose-limiting nephro- and neurotoxicity
forced clinicians to cease using this potent antibiotic.6,7
Colistin comprises a cyclic heptapeptide and tripeptide side
chain acylated at the N-terminus by a fatty acid. Commercially
available colistin contains at least 30 diﬀerent components, 13
of which have been isolated and identiﬁed.8,9 The major
components are colistin A (polymyxin E1) and colistin B
(polymyxin E2) which, together, account for more than 85% of
the total weight of the raw material (Figure 1A).10 The two
substances diﬀer in the length of the fatty acid side chain by
one methylene group.
We have recently employed polymer masked−unmasked
protein therapy (PUMPT) to deliver colistin conjugated to
dextrin using nonspeciﬁc carbodiimide conjugation chemis-
try.11 PUMPT uses conjugation of a biodegradable polymer,
such as dextrin, hyaluronic acid, or poly(L-glutamic acid), to
mask a protein or peptide’s activity.12−14 Following intra-
venous administration, colistin is expected to localize and
accumulate within sites of inﬂammation by the enhanced
permeability and retention (EPR) eﬀect,11,15,16 where the
antibiotic can be released from the conjugate via amylase-
triggered degradation of dextrin. Reinstatement of the
payload’s biological activity may be controlled by employing
dextrins of diﬀerent molecular weights and degrees of
modiﬁcation, tailoring the conjugation chemistry and by the
degree of inﬂammation/enzymatic activity at the “target”
site.11,14 In contrast to the administration of growth factors to
induce healing,17 anti-infective therapy requires rapid delivery
of the antibacterial payload at the site of infection. Previous
studies of dextrin−colistin conjugates have attempted to
optimize dextrin−colistin conjugate’s release kinetics by
varying the molecular weight and degree of succinoylation of
dextrin.11 Ferguson et al. demonstrated that conjugates
containing 7500 g/mol dextrin with 1 mol % succinoylation
resulted in the release of ∼80% of the bound drug within 48 h
when incubated with physiological levels of amylase (100 IU/
L).11 Dextrin−colistin conjugates exhibited reduced in vitro
and in vivo toxicity and prolonged plasma half-life (dextrin−
colistin t1/2 = 135 min, colistin t1/2 = 53 min).
11 Sustained,
concentration-dependent killing of A. baumannii was observed
in an in vitro pharmacokinetic−pharmacodynamic model, and
unmasking of the conjugate in human wound exudate was
conﬁrmed.15 The conjugates also demonstrated antibacterial
activity (against Gram-negative pathogens) similar to the
commercially available prodrug, colistin methanesulfonate
(CMS, Colomycin). Interestingly, however, even after
complete unmasking, antimicrobial activity remained lower
than the unmodiﬁed drug; being more pronounced in
conjugates containing dextrin with higher degrees of
modiﬁcation.11
Whilst the concept of PUMPT is well established, the degree
to which unmasking must occur to completely reinstate the
payload’s bioactivity has not yet been determined. In the
dextrin−colistin conjugate model, α-amylase randomly cleaves
the dextrin backbone, yielding the disaccharides, maltose and
iso-maltose.18 The dextrin is, however, attached to colistin via a
nondegradable amide bond; therefore, even after complete
degradation of dextrin, substituent groups will remain attached
to colistin (Figure 1B). Their presence may explain the
inability to completely reinstate antibiotic activity following
exposure to amylase. In the present work, we hypothesize that
these remaining substituent groups, particularly the number of
glucose units, may strongly aﬀect antimicrobial properties of
the unmasked conjugate. Here, the chemical composition of
diﬀerentially degraded dextrin−colistin conjugates is reported
and related to the species’ biological activity and in vitro
toxicity, to determine the optimal extent of conjugate
Figure 1. (A) Chemical structure of the two subgroups of colistin. (B) Schematic representation of the degradation of the dextrin−colistin
conjugate by α-amylase. Amylase hydrolyzes dextrin at random locations along its chain to yield the disaccharides maltose and iso-maltose,
resulting in a decrease in dextrin’s chain length by x D-glucose units, where n is the DP of the polymer.
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unmasking that is required to achieve maximal antimicrobial
activity.
2. MATERIALS AND METHODS
2.1. Materials. Type I dextrin from corn (Mw = 7500 g/
mol), colistin sulfate, α-amylase from human saliva, N-
hydroxysulfosuccinimide (sulfo-NHS), 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT), bicinchoninic
acid (BCA) solution, and dimethyl sulfoxide (DMSO) maltose
oligomers [degree of polymerization (DP) 2, 3, 6, and 7] were
purchased from Sigma-Aldrich (Poole, U.K.). 1-Ethyl-3-(3-
(dimethylamino)propyl carbodiimide hydrochloride) (EDC)
was acquired from Pierce (Rockford, USA). Disodium
hydrogen phosphate, potassium dihydrogen phosphate,
potassium chloride, 4-dimethylaminopyridine, and sodium
chloride were from Fisher Scientiﬁc (Loughborough, U.K.).
Pullulan gel ﬁltration standards (Mw = 11 800−210 000 g/
mol) were purchased from Polymer Laboratories (Church
Stretton, U.K.). Unless otherwise stated, all chemicals were of
analytical grade and used as received. All solvents were of
general reagent grade (unless stated) and were from Fisher
Scientiﬁc (Loughborough, U.K.).
2.2. Bacterial Culture. Bacterial colonies were grown on
blood agar supplemented with 5% horse blood, and liquid
cultures were suspended in a tryptone soya broth for overnight
culture or Mueller−Hinton broth (MHB) for minimum
inhibitory concentration (MIC) determination (Oxoid;
Basingstoke, U.K.). Antibacterial activity was screened against
an E. coli clinical isolate (V5) provided by Professor Timothy
Walsh (Department of Infection and Immunity, Cardiﬀ
University). Its known relevant genotype and origin have
been described by Khan et al.19
2.3. Cell Culture. Human kidney proximal tubule cells
(HK-2) were obtained from ATCC (Manassas, USA) and
screened to be free of mycoplasma contamination before use.
Keratinocyte serum-free medium (K-SFM) with L-glutamine,
epidermal growth factor (EGF), bovine pituitary extract
(BPE), and 0.05% w/v trypsin-0.53 mM ethylenediaminetetra-
acetic acid were obtained from Invitrogen Life Technologies
(Paisley, U.K.).
2.4. Synthesis of Dextrin−Colistin Conjugates. Dex-
trin−colistin conjugates were synthesized using EDC and
sulfo-NHS and characterized as previously described.11 The
dextrin−colistin conjugate used in these studies contained
dextrin (Mw = 7500 g/mol; DP = 50) with 1 mol %
succinoylation, a colistin content of 7.6% w/w (by BCA assay)
(equivalent to 2 dextrin chains per colistin), and a molecular
weight of 10 000 g/mol (by gel permeation chromatography
with pullulan standards, Mw/Mn = 1.5). Free colistin content,
analyzed by fast protein liquid chromatography (LC), was
determined as <4%. The characteristics of dextrin−colistin
conjugates used to analyze the eﬀect of succinoylation on the
degree of peptide modiﬁcation are summarized in Table S1.
2.5. Amylase Degradation of Dextrin−Colistin Con-
jugates. Unmasked dextrin−colistin conjugates were prepared
by incubation of the dextrin−colistin conjugate (3 mg/mL
colistin base in PBS, pH 7.4) with amylase (100 IU/L) for up
to 48 h at 37 °C. Samples were subsequently lyophilized and
stored at −20 °C prior to analysis.
2.6. Analysis of Masked−Unmasked Conjugates and
Fractionation by SEC. Samples (10−100 mg) were dissolved
in 4 mL of 0.1 M ammonium acetate (pH 6.9, 0.22 μm ﬁlter-
sterilized) and then manually injected into an 8 mL sample
loop. The size exclusion chromatography (SEC) system
consisted of 3 serially connected HiLoad Superdex 30 columns
(2.6 × 60 cm), a Shimadzu LC-10 AD vp pump, a Shimadzu
SPD-10 AV vp UV-detector (215 nm), and a Shodex RI-101
refractive index detector. Data were collected with an Adam
view 4561 converter and a 4017P input module. Samples were
eluted at a ﬂow rate of 0.8 mL/min and fractions collected
every 50 min between 400 and 800 min and stored at −20 °C
until lyophilization. Lyophilized samples were dissolved in MQ
water and then freeze-dried (×5) to remove ammonium
acetate. Total protein content of the degraded fractions was
determined by the BCA assay using colistin standards.
2.7. Characterization of the Collected Fractions by
LC−Mass Spectrometry. Colistin (10 μg/mL, 5 μL) and
fractions (1 mg/mL total weight, 5 μL) were analyzed on a
Synapt G2-Si quadrupole time-of-ﬂight (QTOF) mass
spectrometer (Waters, UK) operating in the positive electro-
spray ionization mode, coupled to an ACQUITY H-Class
UPLC system (Waters, UK). Separation was performed using
an ACQUITY UPLC CSH C18 column (300 Å, 1.7 μm, 2.1 ×
100 mm, Waters) held at 40 °C with a ﬂow rate of 0.3 mL/
min. A multistep gradient method using 98% A for 2 min
followed by a linear gradient to 50% A for 18 min, where A is
water (0.1% formic acid) and B is acetonitrile (0.1% formic
acid).
2.8. Analysis of Unmasked Conjugate by High-
Performance Anion Exchange Chromatography with
Pulsed Amperometric Detection. Samples (0.1−1 mg/mL
total weight) were analyzed using a Dionex ICS-5000+ ion
chromatography system (Thermo Scientiﬁc, Oslo, Norway)
with an electrochemical detector ﬁtted with a nondisposable
gold working electrode. Samples were injected via a 25 μL
loading loop. Separation was performed using a CarboPac PA-
100 (4 × 50 mm, Dionex) guard column and CarboPac PA-
100 (4 × 250 mm, Dionex) analytical column connected held
at 24 °C with a ﬂow rate of 1 mL/min. Analysis was performed
using isocratic 100 mM sodium hydroxide and a linear sodium
acetate gradient from 10 to 610 mM in 90 min. A Carboquad
waveform was used for detection. Data were collected and
processed using Chromeleon 7.2 software.
2.9. Measurement of Antimicrobial Activity. Anti-
microbial activity was measured using broth microdilution in a
standard MIC assay.20 E. coli strain, V5, was suspended in
MHB (100 μL, 1 to 5 × 104 CFU/mL) and incubated in 96-
well microtiter plates in serial twofold dilutions of the test
compounds. To prepare initial dilutions, samples were
dissolved in PBS at 50 μg/mL (colistin base) and then diluted
in MHB to a starting concentration of 16 μg/mL colistin.
Experiments were performed in triplicate and expressed as the
modal value.
2.10. Bacterial Growth Curves. The pharmacokinetic
proﬁle of individual fractions was studied against E. coli.
Colistin and the derived fractions (with 4 μg/mL starting
colistin concentration) were added to 96-well microtiter plates
in serial twofold dilutions. Plates were wrapped in Paraﬁlm M
and placed in a microtiter plate reader at 37 °C; bacterial
growth was assessed by measuring absorbance (at 600 nm),
hourly, for 48 h. The absorbance values were expressed as
mean ± standard deviation (SD) (n = 3).
2.11. Confocal Laser Scanning Microscopy and
COMSTAT Analysis. The direct eﬀects of the analytes were
studied using confocal laser scanning microscopy (CLSM)
imaging. E. coli bioﬁlms were grown in Grenier 96-well glass-
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bottomed plates in MHB ± colistin or degraded fractions. A
1:10 inoculum of E. coli overnight culture (1 × 107 CFU/mL)
was used, and plates were incubated at 37 °C for 24 h. The
supernatant was carefully removed from the plates, and the
bioﬁlms were stained with LIVE/DEAD (Baclight Bacterial
Viability Kit, Molecular Probes) for 10 min before imaging
using a Leica SP5 CLSM. CLSM images were achieved with a
×63 lens (oil) and a step size of 0.79 μm. The resultant CLSM
z-stack images were analyzed using COMSTAT image analysis
software for quantiﬁcation of three-dimensional bioﬁlm
structures through measurement of biomass, mean bioﬁlm
thickness, roughness coeﬃcient, and DEAD/LIVE bacterial
ratio.21 Statistical calculations were performed using Minitab
v.14 (Minitab, State College, PA). To determine signiﬁcant
diﬀerences for pair-wise comparisons, the nonparametric data
were analyzed using the Mann−Whitney test. A p value < 0.05
was considered statistically signiﬁcant.
2.12. In Vitro Cytoxicity. An MTT assay was used to
assess cell viability in a human kidney (HK-2) cell line (72 h
incubation). HK-2 cells (passages P15 to P20) were seeded
into sterile 96-well microtiter plates (2.5 × 104 cells/mL) in
0.1 mL/well of media (K-SFM) containing L-glutamine, EGF,
and BPE and allowed to adhere for 24 h. The medium was
then removed, and test compounds were added to the wells.
To study the eﬀect of colistin sulfate, fraction F8, and intact
dextrin−colistin conjugate on cell viability, complete media
were supplemented with a range of diﬀerent concentrations of
each. After a further 67 h incubation, MTT (20 μL of a 5 mg/
mL solution in PBS) was added to each well and incubated for
a further 5 h. The medium was then removed, and the
precipitated formazan crystals solubilized by the addition of
optical grade DMSO (100 μL). After 30 min, the absorbance
of each well was measured at 540 nm using a microtiter plate
reader. Cell viability was expressed as a percentage of the
viability of untreated control cells and expressed as mean ±
standard error of the mean (SEM) (n = 18). Evaluation of
signiﬁcance was achieved using a two-way analysis of variance
(ANOVA) followed by Bonferroni post hoc tests that correct
for multiple comparisons. All statistical calculations were
performed using a GraphPad Prism, version 6.0h for
Macintosh, 2015.
3. RESULTS
3.1. Chemical Characterization of Degraded Frac-
tions. SEC-RI of the dextrin−colistin conjugate after amylase
unmasking showed a decrease of the peak corresponding to the
conjugate (400−750 min) (Figure 2A). This was mirrored by
the appearance of a peak corresponding to a species with a
molecular weight close to that of colistin (retention time ∼760
min), which was also observed by SEC-UV (Figure 2B). SEC-
RI revealed peaks corresponding to water, ammonium acetate
salts, and glucose (∼1000 min), whereas added sodium
chloride and phosphate salts eluted at ∼1050 min. Several
oligosaccharides, released by the degradation of dextrin, were
also observed (850−950 min). High-performance anion
exchange chromatography with pulsed amperometric detection
(HPAEC-PAD) revealed that the most intense peaks
corresponded to maltose (DP = 2) and maltotriose (DP =
3) (Figure S1). Therefore, assuming that the intensity of the
peaks observed by HPAEC-PAD mirrored those observed by
SEC-RI, the two major peaks observed by the latter at 926 and
951 min were identiﬁed as maltotriose and maltose,
respectively. Analysis of the protein content of individual
fractions revealed that fraction F8 (750−800 min retention
time) contained the highest amount of colistin (38.8% w/w)
compared to fractions F1−7 (400−750 min retention time,
2.1−5.5% w/w) (Table 1).
LC−mass spectrometry (MS) analysis revealed distinct
structural diﬀerences between individual fractions and
unmodiﬁed colistin (Table S2). Figure 3 illustrates ultra-
performance liquid chromatography (UPLC) chromatograms
and the corresponding mass spectra are shown in Figures S2−
S5. Colistin’s UPLC chromatogram revealed two main peaks at
5.6 and 6.4 min, corresponding to colistin B and colistin A,
respectively (Figure 3A). The chromatogram for fraction F8
contained a peak at 1.2 min, corresponding to oligosaccharides
with DP 7−13 (1200−2100 g/mol) (Figure 3B). MS analysis
of the peak revealed an intense peak at m/z 839.22,
Figure 2. SEC chromatograms of colistin (black), dextrin−colistin
conjugate (blue), and α-amylase-treated (48 h at 37 °C) dextrin−
colistin conjugate (red) by (A) RI detection and (B) UV detection (λ
= 215 nm). Collected fractions are shown in orange.
Table 1. Protein Content and Antimicrobial Activity (Mode
MIC, n = 3) of Colistin Sulfate and Collected Fractionsa
fractions protein content (% w/w) MIC (μg/mL)
F1 2.1 4
F2 3.2 4
F3 2.9 8
F4 3.2 8
F5 3.4 4
F6 3.9 4
F7 5.5 2
F8 38.8 0.25
colistin 100 1.95 × 10−3
aData is expressed as mode (n = 3); MIC value represents equivalent
colistin base concentration of fractions.
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corresponding to an oligosaccharide with DP10 (Figure S3). In
addition, the UPLC chromatogram of fraction F8 revealed
multiple peaks, corresponding to colistin A and B attached to
one linker ± H2O (7.2−8.6 min) and colistin A and B bound
to two linkers −1 or 2 H2O (8.9−10.4 min) (Figure 3B).
Colistin A and B bound to two linkers without the loss of H2O
were not observed. Interestingly, peaks corresponding to the
same molecular mass were observed at diﬀerent retention
times. The UPLC chromatogram for fraction F7 contained a
peak at 1.1 min, corresponding to dehydrated oligosaccharides
with DP 7−18 (1200−2900 g/mol) (Figure 3C). The MS
analysis of the peak revealed the most intense peak at m/z
1135.38, which corresponded to an oligosaccharide with DP14.
In addition, peaks in the UPLC chromatogram between 7.5
and 7.9 min were observed, which corresponded to colistin B
attached to 1−6 glucose units via a single linker ± H2O.
Similarly to fractions F7 and F8, the UPLC chromatogram for
fraction F6 contained a peak at 1.1 min, which corresponded to
oligosaccharides with DP 13−22 (2100−3600 g/mol) (Figure
3D). The most intense peak by MS was detected at m/z
1468.44, corresponding to DP18. A peak was also observed at
7.9 min, which corresponded to colistin B attached to 6−8
glucose units via a single linker and colistin A attached to 6−13
glucose units via a single linker. Sharp peaks observed between
3.5 and 6.5 min and above 9.5 min were impurities.
LC−MS analysis of unfractionated amylase-degraded
dextrin−colistin conjugates with diﬀerent degrees of succinoy-
lation (1.0, 2.5, and 7.5 mol %) revealed structural diﬀerences
in released species (Figures S6 and S7, Table S3). Whereas the
UPLC chromatogram for dextrin−colistin conjugates contain-
ing 1.0 mol % succinoylated dextrin contained considerably
more colistin A and B bound to only one linker, the UPLC
chromatogram for the degraded conjugate containing 2.5 mol
% succinoylated dextrin revealed peaks corresponding to an
almost equal proportion of colistin A and B bound to one
(6.8−8.8 min) or two (8.8−11 min) linkers −1 to 2 H2O.
Smaller peaks corresponding to colistin A and B bound to 3
linkers −1 to 3 H2O (11−13.4 min) were also observed. When
the degree of dextrin succinoylation was increased to 7.5 mol
%, the intensity of peaks corresponding to colistin A and B
bound to 2 or 3 linkers increased. This was mirrored by a
decrease in the intensity of peaks corresponding to colistin A
and B with a single linker attached. In all cases, the maximum
number of water molecules lost from the species was equal to
the number of linkers attached to colistin; species with the
greatest loss of water appeared later in the UPLC chromato-
gram.
3.2. Biological Activity of Degraded Fractions. All of
the fractions analyzed exhibited lower antimicrobial activity
than unmodiﬁed colistin (7−12 log-fold reduction in MIC),
which varied between fractions. Antimicrobial activity was
signiﬁcantly higher for fraction F8, corresponding to fully
unmasked colistin, than fractions corresponding to colistin
with oligosaccharide chains attached (up to 5 log-fold
reduction in MIC) (Table 1). The MIC value of the intact
conjugate was 2 μg/mL, which is equivalent to the MIC of the
bound fractions (from F1 to F7). Whilst fraction F8 (at 1/4
MIC, 0.0625 μg/mL colistin equiv) signiﬁcantly delayed E. coli
growth (by up to 10 h), fractions F6 and F7 showed limited
eﬀect on bacterial growth, even at 1/2 MIC (1 and 2 μg/mL
colistin equiv, respectively) (Figure 4). Bacterial lag time in the
presence of colistin at 1/4 and 1/2 MIC (4.88 × 10−3 and 9.77
× 10−3 μg/mL colistin equiv, respectively) was at least half that
of bacteria grown in the presence of fraction F8 at 1/4 and 1/2
MIC (0.0625 and 0.125 μg/mL colistin equiv, respectively)
(Figure 4c). Observations in the planktonic culture systems
were reﬂected in the eﬀects of the fractions in bacterial bioﬁlm
systems. Fraction F8, at 2× MIC (0.5 μg/mL colistin equiv),
eﬀectively inhibited bioﬁlm formation (Figure 5A). COM-
STAT analysis of CLSM images revealed that this was
Figure 3. UPLC−QTOF-MS chromatograms (base peak intensity) of
(A) colistin (10 μg/mL), (B) F8 (1 mg/mL), (C) F7 (1 mg/mL),
and (D) F6 (1 mg/mL).
Figure 4. Bacterial growth curves for E. coli (48 h) in the presence of
colistin sulfate and fractions F6, F7, and F8 at (A) 1/2 MIC and (B)
1/4 MIC (colistin base) (mean ± SD; n = 3). Corresponding lag
times are indicated next to the ﬁgures. Panel (C) shows bacterial
growth lag time, determined using an absorbance threshold of 0.1.
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associated with a signiﬁcant reduction in bioﬁlm biomass and
thickness and a signiﬁcant increase in roughness coeﬃcient and
bacterial cell death (p < 0.05, vs control; Figure 5B). Whereas
fraction F7, at the same concentration, had no signiﬁcant eﬀect
on bioﬁlm formation, fraction F6 caused a signiﬁcant increase
in bioﬁlm thickness and biomass (p < 0.05, vs control). When
bioﬁlms were grown in the presence of fractions at the MIC
observed for F8 (0.25 μg/mL colistin equiv), no signiﬁcant
eﬀect on bioﬁlm formation was observed in the presence of
fractions F8 and F7, whereas treatment with fraction F6 caused
a signiﬁcant increase in bioﬁlm biomass and thickness,
mirrored by a decrease in roughness coeﬃcient (Figure S8)
(p < 0.05, vs control). In comparison, colistin at 0.25 and 0.5
μg/mL (equivalent to fraction F8’s MIC and 2× MIC,
respectively) caused complete inhibition of bioﬁlm formation,
whereas no eﬀect on bioﬁlm formation was observed when
bioﬁlms were grown at 0.002 and 0.004 μg/mL (equivalent to
colistin’s MIC and 2× MIC) (Figure 5C,D). Although
antibacterial activity of the fully unmasked colistin was lower
than the parent drug, in vitro cytotoxicity of fraction F8 was
statistically less cytotoxic than both, unmodiﬁed colistin and
intact dextrin−colistin conjugate in human kidney cells (Figure
6).
4. DISCUSSION
In the last decades, biodegradable polymers have grown in
popularity because of their ability to reduce the bioactive’s
antigenicity, extend circulatory half-life, and release the payload
by degradation of the polymer at the target site.22−24
Biodegradable polymers have the added advantage of enabling
the use of much larger polymers because they are not limited
to the renal threshold. Our previous studies, using dextrin−
colistin conjugates, suggested that colistin’s antibacterial
activity is greatest when it was attached to shorter chains of
dextrin with minimal modiﬁcation;11 however, the composi-
tion of the active species and the extent to which the polymer
must be degraded to restore biological activity has not been
deﬁned in any studies relating to PUMPT.12 An accurate
deﬁnition of the “bound” and “free” species and identiﬁcation
of the structure−activity relationship are needed to develop
and validate a chromatographic detection method to assess the
pharmacokinetics and tissue distribution of dextrin−colistin
conjugates. In previous studies, a colistin enzyme-linked
immunosorbent assay kit was used to measure the
pharmacokinetics; however, this method is unable to
distinguish between “free” (active) and dextrin-bound
(inactive) colistin.11 In this study, fractionation of degraded
dextrin−colistin conjugate by SEC followed by analysis using
LC−MS and biological assays has been used to speciﬁcally
determine the molecular structure of the active species.
4.1. Chemical Characterization. SEC-RI of the dextrin−
colistin conjugate after amylase unmasking was successfully
used to obtain fractions containing saccharides and colistin-
based species with diﬀerent molecular weights. Character-
ization of the molecular structure of low molecular weight
derivatized peptides and conjugates is complex, necessitating
the use of highly sensitive detection methods such as MS.25
Because interpretation of MS data requires deconvolution of
molecular fragments, in these studies, LC−MS was only
performed on fractions corresponding to lower molecular
weight species. LC was employed instead of direct injection as
a separation of colistin-based species from released saccharides
would make identiﬁcation of the species more straightforward.
Analysis of fraction F8 revealed a range of colistin-containing
species, reﬂecting the heterogeneous composition of the
conjugates due to nonspeciﬁc binding of dextrin to the 5
amino groups of colistin. This is also witnessed by the presence
of peaks with diﬀerent retention times corresponding to
structures with the same molecular mass. This has been
described previously; poly(ethylene glycol) (PEG)−protein
Figure 5. Bioﬁlm formation assay showing LIVE/DEAD (green and
red colors, respectively) stained CLSM images of E. coli bioﬁlms
(aerial and side view, scale bar = 40 μm) grown for 24 h in the
presence of (A) fractions F6, F7, and F8 at 0.5 μg/mL colistin base
(equivalent to 2× fraction F8’s MIC) and (C) colistin sulfate at 0.25
and 0.5 μg/mL colistin base, MIC and 2× MIC. COMSTAT image
analysis of bioﬁlm CLSM z-stack images for (B) fractions and (D)
colistin sulfate. Data represent mean ± SD; n = 3. Signiﬁcant
diﬀerence is indicated by *, where *p < 0.05, compared to untreated
control.
Figure 6. In vitro cytotoxicity of colistin sulfate, fraction F8, and
intact dextrin−colistin conjugate (1 mol % succinoylation). Cell
viability was assessed by MTT assay of HK-2 cells (72 h incubation)
at 50, 100, and 250 μg/mL colistin base. Data are expressed as mean
% untreated control ± SEM, n = 18. Signiﬁcant diﬀerence is indicated
by *, where **p < 0.01 and ***p < 0.001. For the conjugate, errors
bars are too small to be visible.
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positional isomers and multiple PEGylated products are
common, resulting from “nonselective” conjugation to several
nucleophilic groups (e.g., lysine residues and terminal amine)
on the protein.26,27 This has led to researchers exploring site-
selective conjugation methods.28,29
The presence of linkers attached to colistin’s amino groups
increased its hydrophobicity. Thus, the species with more
linkers attached appeared later in the UPLC chromatogram.
Here, we showed that with increasing degree of succinoylation,
the number of linkers bound to colistin also increased.
Previously, we used a ninhydrin assay to quantify the number
of free amino groups following conjugation, which estimated
that each colistin molecule was attached to dextrin via ∼3 NH2
groups, regardless of the succinoylation rate.11 However, this
method is unlikely to be as precise as LC−MS used here.
Typically, increasing the extent of bioactive modiﬁcation will
reduce the bioactive’s antigenicity and extend its circulation
half-life; however, this may be accompanied by a loss of the
bioconjugate’s pharmacological activity.30 Our observations
here may explain the reduced antimicrobial activity of
conjugates containing dextrins with a higher degree of
succinoylation, observed in our previous studies,11 as well as
that of other researchers.12
High-performance LC has previously been used to
investigate the stability of commercial forms of the colistin
prodrug, CMS, which readily undergoes random hydrolysis of
the ﬁve sulfomethyl groups in aqueous solutions, resulting in
up to 32 products.31−33 In the same way as dextrin conjugation
decreases colistin’s in vitro antibacterial potency, so too does
sulfomethylation.34−36 CMS is an inactive prodrug of
colistin.37 However, although amylase-triggered release of
colistin released up to 80% free drug after 24 h in vitro,11
conversion eﬃciency of CMS to colistin in the same period
varies from 23 to 80% in vitro (in water, phosphate buﬀer and
human plasma at 37 °C),11,31 whereas only 30% of the prodrug
is converted to colistin in vivo, as the remaining 70% of the
CMS dose administered is excreted intact in the urine.31 In
contrast, colistin is not cleared renally and dextrin−colistin
conjugates have demonstrated an extended plasma half-life
following IV administration to rats.11
4.2. Biological Activity. Colistin is a highly potent
antibiotic that has retained activity against most Gram-negative
MDR strains.38−41 In previous studies, MIC assays showed
greater antimicrobial activity from dextrin−colistin conjugates
containing colistin with fewer and shorter chains of minimally
modiﬁed dextrin attached.11 Similarly, Zhu et al. observed
reduced antibiotic activity from bi-PEGylated colistin,
compared to the mono-PEGylated antibiotic, which was
attributed to the former’s larger molecular weight and slower
colistin release rate.42 Previously, pre-incubation of dextrin−
colistin conjugates with physiological concentrations of
amylase only reduced the MIC value by 1 log-fold, compared
to the untreated conjugate;11 however, these studies used a
crude mixture of degraded conjugate, composed of a
heterogeneous mixture of diﬀerentially degraded conjugates,
which may mask the eﬀect of the active species. Indeed, these
studies showed a clear distinction in antimicrobial activity of
fraction F8 and the larger fractions of degraded conjugate
(which had an equivalent MIC to the intact dextrin−colistin),
suggesting that complete degradation of dextrin is required to
reinstate maximal antibiotic activity. Chemical characterization
of fraction F8 showed that colistin retained a linker group
attached to it, even after complete polymer degradation. This is
in contrast to CMS, where complete hydrolysis of all of the
sulfomethyl groups forms the parent drug, colistin. Because
colistin’s interaction with anionic lipopolysaccharide molecules
on the outer membrane of Gram-negative bacteria is mediated
via its 5 amine groups43 and dextrin is conjugated to colistin
via at least one of these groups, it is not surprising that the
antibacterial activity is reduced by the presence of a linker
group at this site. Interestingly, of the 10 novel polymyxin
derivatives that have been shown to be more eﬀective than
conventional polymyxins in animal infection models, 8 of them
retain all ﬁve Dab residues, conﬁrming the importance of the
positively charged amine groups for antimicrobial activity.44 A
similar inability to completely recover the bioactive’s biological
activity (following enzymatic polymer degradation) has also
been observed when hyaluronan was conjugated to EGF, using
similar conjugation chemistry;13 a ﬁnding attributed to the
presence of oligosaccharides attached to the lysine residue
close to EGF’s receptor-binding domain. In previous antibiotic
conjugation models, in an attempt to maximize antibiotic
activity, Zhu et al. used a labile ester linker in their mono-
PEGylated colistin to facilitate release of drug that was
chemically identical to unmodiﬁed colistin and retained similar
activity to the native peptide.42 Here, treatment with fraction
F6 counter-intuitively induced signiﬁcant bioﬁlm growth,
presumably because of the bacteria using the longer
oligosaccharide chains as a carbon- and energy source.
In practice, systemic administration of colistin may be
restricted by dose-limiting nephrotoxicity, which occurs due to
reabsorption and accumulation of colistin in renal tubular
cells.11 Previous studies showed that dextrin conjugation
reduced colistin’s in vitro cytotoxicity toward human kidney
proximal tubule (HK-2) cells, with around a four−ﬁvefold
improved IC50 concentration.
11 Even after amylase-unmasking
of dextrin−colistin conjugates, cytotoxicity remained similar to
the intact conjugate and less than colistin sulfate. Given the
heterogeneous composition of this crude mixture, it was
important in the current study to test the cytotoxicity of the
individual fractions. Whilst the ﬁnding that fraction F8 was
signiﬁcantly less toxic in vitro than the intact dextrin−colistin
conjugate appeared surprising, Zhu et al. demonstrated that
colistin attached to a single PEG chain failed to induce
histological renal damage in vivo at 40 mg colistin equiv/kg,
but the presence of 2 PEG chains, however, resulted in renal
tubular injury.42 The authors attributed this diﬀerence in
nephrotoxicity to the complex and diﬀerent renal handling
mechanisms of the mono- and di-PEGylated colistin. Here, the
reduced toxicity observed in fraction F8, compared to the
intact dextrin−colistin conjugate, may reﬂect altered uptake
and accumulation by HK-2 cells because of the oligosacchar-
ides attached to colistin.
4.3. Future Perspectives. Our ultimate goal is to develop
and validate a chromatographic detection method to study
degradation and biodistribution of dextrin−colistin conjugates
following in vivo administration by analysis of serum and other
biological samples (e.g., macerated organs). Method develop-
ment is ongoing but challenging because the chemical diversity
of the released species precludes the use of reversed-phase
separation and the low absorbance of colistin necessitates the
use of a derivatization method that will not be aﬀected by
residual saccharide moieties. The results of these structure−
activity relationship studies demonstrate that complete
unmasking of colistin is required for maximum antibiotic
activity. Because the smallest fractions may not localize as
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eﬃciently to sites of infection by the EPR eﬀect and are likely
to be cleared faster from the body, ideally, unmasking should
occur predominantly at the target site. We have previously
shown that the α-amylase activity is signiﬁcantly higher in
infected wound ﬂuid compared to that in patient-matched
serum (408.4 and 60.0 IU/L, respectively),15 which suggests
that this could be feasible. Ongoing studies are developing an
in vivo mouse model to test this hypothesis and quantify the
amount of “free”/active and “bound”/inactive colistin in
biological samples.
5. CONCLUSIONS
This study highlights the importance of deﬁning the structure−
antimicrobial activity relationship for novel antibiotic deriva-
tives. Here, we have demonstrated that the presence of
functional groups attached to colistin signiﬁcantly aﬀects its
biological activity, and this eﬀect can be minimized (but not
fully reversed) by enzymatic degradation of the polymer. LC−
MS is a valuable tool for characterizing conjugation patterns,
which can aid in the design of biodegradable polymer−
antibiotic conjugates, as well as for studying drug distribution
and disposition in vivo.
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